Novel melatonin-based treatments for major depression

The Lancet

Volumn 379, Issue 9812, 2012, Pages 217-

  Serfaty, Marc ^a   Raven, Peter W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; MELATONIN; PLACEBO;

ANTIDEPRESSANT ACTIVITY; COST CONTROL; EFFECT SIZE; HUMAN; LETTER; MAJOR DEPRESSION; PRIORITY JOURNAL; NOTE;

DEPRESSIVE DISORDER, MAJOR; HUMANS; MELATONIN;

EID: 84856115645     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60098-1     Document Type: Letter

References (4)

1. IB Hickie, NL Rogers Novel melatonin-based therapies: potential advances in the treatment of major depression Lancet 378 2011 621 631
2. JS Carman, RM Post, R Buswell, FK Goodwin Negative effects of melatonin on depression Am J Psychiatry 133 1976 1181 1186
3. MA Serfaty, D Osborn, MJ Buszewicz, R Blizard, PW Raven A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood Int Clin Psychopharmacol 25 2010 132 142
4. N Buscemi, B Vandermeer, N Hooton et al. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis BMJ 332 2006 385 388 (Pubitemid 43797377)